Do analysts prefer REVB or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is REVB or PRFX more profitable?

PainReform's return on equity of 0.00% beat Revelation Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -107.65% -87.98% PainReform N/A N/A N/A

Do analysts prefer LABT or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LABT or PRFX more profitable?

Company Net Margins Return on Equity Return on Assets Lakewood-Amedex Biotherapeutics N/A N/A N/A PainReform N/A N/A N/A

Does the media refer more to LABT or PRFX?

In the previous week, Lakewood-Amedex Biotherapeutics and Lakewood-Amedex Biotherapeutics both had 2 articles in the media. PainReform's average media sentiment score of 0.96 beat Lakewood-Amedex Biotherapeutics' score of 0.94 indicating that PainReform is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakewood-Amedex Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PainReform 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PRFX or SXTP?

60 Degrees Pharmaceuticals has a consensus price target of $13.85, suggesting a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than PainReform. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PRFX or SXTP more profitable?

PainReform has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A 60 Degrees Pharmaceuticals -574.91% N/A -131.48%

Do analysts recommend PRFX or CAPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend PRFX or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is PRFX or CELZ more profitable?

PainReform's return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Creative Medical Technology N/A -88.38% -84.71%

PainReform (PRFX) Competitors

$1.14 -0.02 (-1.30%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.12 -0.02 (-1.76%)

As of 07/24/2026 07:23 PM Eastern

Compare

PRFX vs. REVB, LABT, SXTP, CAPS, and CELZ

Should you buy PainReform stock or one of its competitors? MarketBeat compares PainReform with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PainReform include Revelation Biosciences (REVB), Lakewood-Amedex Biotherapeutics (LABT), 60 Degrees Pharmaceuticals (SXTP), Capstone Therapeutics (CAPS), and Creative Medical Technology (CELZ). These companies are all part of the "pharmaceutical products" industry.

How does PainReform compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

PainReform's return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-107.65%	-87.98%
PainReform	N/A	N/A	N/A

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Revelation Biosciences has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market. Comparatively, PainReform has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

In the previous week, PainReform had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 2 mentions for PainReform and 1 mentions for Revelation Biosciences. PainReform's average media sentiment score of 0.96 beat Revelation Biosciences' score of 0.94 indicating that PainReform is being referred to more favorably in the news media.

Company	Overall Sentiment
Revelation Biosciences	Positive
PainReform	Positive

PainReform has higher revenue and earnings than Revelation Biosciences. Revelation Biosciences is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A
PainReform	$17K	58.02	-$5.02M	-$736.66	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PainReform beats Revelation Biosciences on 10 of the 11 factors compared between the two stocks.

How does PainReform compare to Lakewood-Amedex Biotherapeutics?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and PainReform (NASDAQ:PRFX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

37.3% of PainReform shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than PainReform. Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	-$2.00	N/A
PainReform	$17K	58.02	-$5.02M	-$736.66	N/A

In the previous week, Lakewood-Amedex Biotherapeutics and Lakewood-Amedex Biotherapeutics both had 2 articles in the media. PainReform's average media sentiment score of 0.96 beat Lakewood-Amedex Biotherapeutics' score of 0.94 indicating that PainReform is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakewood-Amedex Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PainReform	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
PainReform	N/A	N/A	N/A

Summary

PainReform beats Lakewood-Amedex Biotherapeutics on 5 of the 6 factors compared between the two stocks.

How does PainReform compare to 60 Degrees Pharmaceuticals?

PainReform (NASDAQ:PRFX) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

In the previous week, PainReform had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 2 mentions for PainReform and 1 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat PainReform's score of 0.96 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
PainReform	Positive
60 Degrees Pharmaceuticals	Very Positive

PainReform has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market.

PainReform has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

60 Degrees Pharmaceuticals has a consensus price target of $13.85, suggesting a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

37.3% of PainReform shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 34.4% of PainReform shares are held by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

PainReform has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$17K	58.02	-$5.02M	-$736.66	N/A
60 Degrees Pharmaceuticals	$1.41M	2.79	-$7.36M	-$8.92	N/A

Summary

PainReform beats 60 Degrees Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does PainReform compare to Capstone Therapeutics?

PainReform (NASDAQ:PRFX) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

In the previous week, PainReform had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 2 mentions for PainReform and 1 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 1.87 beat PainReform's score of 0.96 indicating that Capstone Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PainReform	Positive
Capstone Therapeutics	Very Positive

PainReform has higher earnings, but lower revenue than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$17K	58.02	-$5.02M	-$736.66	N/A
Capstone Therapeutics	$48.11M	0.07	-$21.23M	-$3.37	N/A

PainReform has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. PainReform's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

37.3% of PainReform shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 34.4% of PainReform shares are held by insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PainReform has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.51, meaning that its stock price is 251% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PainReform beats Capstone Therapeutics on 9 of the 13 factors compared between the two stocks.

How does PainReform compare to Creative Medical Technology?

PainReform (NASDAQ:PRFX) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

37.3% of PainReform shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 1.0% of Creative Medical Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PainReform has higher revenue and earnings than Creative Medical Technology. Creative Medical Technology is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$17K	58.02	-$5.02M	-$736.66	N/A
Creative Medical Technology	$10K	383.94	-$5.99M	-$2.14	N/A

In the previous week, PainReform and PainReform both had 2 articles in the media. Creative Medical Technology's average media sentiment score of 1.45 beat PainReform's score of 0.96 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
PainReform	Positive
Creative Medical Technology	Positive

PainReform has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

PainReform's return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Creative Medical Technology	N/A	-88.38%	-84.71%

Summary

PainReform beats Creative Medical Technology on 7 of the 12 factors compared between the two stocks.

Get PainReform News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRFX vs. The Competition

Export

Metric	PainReform	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$999K	$3.08B	$6.87B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	0.00	20.29	27.11	23.64
Price / Sales	58.02	485.19	517.09	89.57
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	0.05	4.13	10.28	6.07
Net Income	-$5.02M	$65.94M	$3.60B	$331.99M
7 Day Performance	-4.62%	-4.16%	-1.27%	-0.63%
1 Month Performance	-29.06%	-3.76%	-0.37%	-2.00%
1 Year Performance	-84.77%	9.94%	18.30%	13.62%

PainReform Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRFX PainReform	0.506 of 5 stars	$1.14 -1.3%	N/A	-84.6%	$999K	$17K	N/A	4
REVB Revelation Biosciences	0.6588 of 5 stars	$1.09 +4.8%	N/A	-91.3%	$4.26M	N/A	N/A	10
LABT Lakewood-Amedex Biotherapeutics	0.8445 of 5 stars	$2.43 -4.7%	N/A	N/A	$4.26M	N/A	N/A	5	Gap Down High Trading Volume
SXTP 60 Degrees Pharmaceuticals	3.4254 of 5 stars	$1.55 +6.2%	$13.85 +793.5%	-72.4%	$4.12M	$1.41M	N/A	3	Gap Up
CAPS Capstone Therapeutics	0.7339 of 5 stars	$0.26 +2.4%	N/A	-85.6%	$4.00M	$51.62M	N/A	38	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRFX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PainReform (PRFX) Competitors

PRFX vs. REVB, LABT, SXTP, CAPS, and CELZ

How does PainReform compare to Revelation Biosciences?

Summary

How does PainReform compare to Lakewood-Amedex Biotherapeutics?

Summary

How does PainReform compare to 60 Degrees Pharmaceuticals?

Summary

How does PainReform compare to Capstone Therapeutics?

Summary

How does PainReform compare to Creative Medical Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PainReform (PRFX) Competitors

PRFX vs. REVB, LABT, SXTP, CAPS, and CELZ

How does PainReform compare to Revelation Biosciences?

Is REVB or PRFX more profitable?

Do insiders & institutionals have more ownership in REVB or PRFX?

Which has more risk and volatility, REVB or PRFX?

Does the media favor REVB or PRFX?

Which has stronger valuation & earnings, REVB or PRFX?

Do analysts prefer REVB or PRFX?

Summary

How does PainReform compare to Lakewood-Amedex Biotherapeutics?

Do analysts prefer LABT or PRFX?

Do insiders & institutionals hold more shares of LABT or PRFX?

Which has stronger valuation and earnings, LABT or PRFX?

Does the media refer more to LABT or PRFX?

Is LABT or PRFX more profitable?

Summary

How does PainReform compare to 60 Degrees Pharmaceuticals?

Does the media favor PRFX or SXTP?

Which has more risk and volatility, PRFX or SXTP?

Is PRFX or SXTP more profitable?

Do analysts recommend PRFX or SXTP?

Do insiders and institutionals hold more shares of PRFX or SXTP?

Which has stronger valuation & earnings, PRFX or SXTP?

Summary

How does PainReform compare to Capstone Therapeutics?

Does the media favor PRFX or CAPS?

Which has stronger valuation and earnings, PRFX or CAPS?

Is PRFX or CAPS more profitable?

Do institutionals and insiders hold more shares of PRFX or CAPS?

Which has more volatility & risk, PRFX or CAPS?

Do analysts recommend PRFX or CAPS?

Summary

How does PainReform compare to Creative Medical Technology?

Do institutionals & insiders believe in PRFX or CELZ?

Which has better valuation and earnings, PRFX or CELZ?

Does the media favor PRFX or CELZ?

Which has more volatility and risk, PRFX or CELZ?

Do analysts recommend PRFX or CELZ?

Is PRFX or CELZ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools